NTRK Fusion-Positive Cancer

1. Disease Information

Overview (current understanding)

NTRK fusion-positive cancer refers to solid tumors (adult or pediatric) that harbor oncogenic gene fusions involving NTRK1, NTRK2, or NTRK3, which encode the TRK receptor tyrosine kinases TRKA/TRKB/TRKC, respectively. These fusions create constitutively active TRK signaling and predict sensitivity to TRK inhibitors in a tumor-agnostic manner. (bungaro2024ntrk123biologydetection pages 5-6, vingiani2023pantrkimmunohistochemistryas pages 1-3)

Synonyms / alternative names (commonly used): - “TRK fusion cancer” (yang2023safetyofcurrent pages 4-6) - “NTRK-rearranged tumors” / “NTRK fusion–positive solid tumors” (nakata2024prevalenceofneurotrophic pages 2-4, besse2026repotrectinibinntrk pages 1-2)

Key identifiers

• ICD-10 / ICD-11 / MeSH / OMIM / Orphanet: Not identified in the retrieved sources as a single unified disease code, consistent with the fact that NTRK fusion-positive cancer is primarily a molecular biomarker state across many histologies, not a single histology-defined disease entity. (bungaro2024ntrk123biologydetection pages 5-6, bungaro2024ntrk123biologydetection pages 2-4)

Evidence sources

Most information is derived from aggregated disease-level resources (pan-cancer cohorts, multi-site clinicogenomic datasets, pooled trial analyses) rather than individual EHR-only sources. (nakata2024prevalenceofneurotrophic pages 2-4, bungaro2024ntrk123biologydetection pages 2-4)

2. Etiology

Disease causal factors (mechanistic)

Primary causal factor: somatic gene fusions involving NTRK1/2/3, produced by intra- or inter-chromosomal rearrangements, that encode oncogenic fusion proteins. Nakata et al. describe that “Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which are oncogenic drivers in various solid tumors.” (Cancer Medicine; 2024-06; https://doi.org/10.1002/cam4.7351) (nakata2024prevalenceofneurotrophic pages 1-2)

Risk factors

Because NTRK fusion-positive cancer is a genomic alteration rather than a specific histology, “risk factors” are best framed as tumor-type and age-group enrichment patterns rather than traditional exposures: - Strong enrichment in some rare/pediatric histologies (e.g., infantile fibrosarcoma, secretory breast carcinoma, congenital mesoblastic nephroma), versus very low prevalence in unselected adult solid tumors. (bungaro2024ntrk123biologydetection pages 2-4) - Pediatric patients show consistently higher NTRK fusion prevalence than adults in large datasets (see Epidemiology). (nakata2024prevalenceofneurotrophic pages 2-4, kubota2025currentmanagementof pages 1-2)

Protective factors / gene–environment interactions

No protective factors or gene–environment interaction evidence was identified in the retrieved sources.

3. Phenotypes

Cross-cutting phenotype concept

Clinical features are largely those of the underlying tumor histology and site, rather than a single shared syndrome. However, two cross-cutting clinical patterns emerge: 1) Age enrichment: pediatric cancers show higher NTRK fusion prevalence than adults. (nakata2024prevalenceofneurotrophic pages 2-4, kubota2025currentmanagementof pages 1-2) 2) Testing context: in large clinicogenomic cohorts, testing tends to occur in advanced/metastatic disease; in the Japanese C-CAT cohort, most profiled patients had metastatic disease at the time of comprehensive genomic profiling (CGP). (nakata2024prevalenceofneurotrophic pages 2-4)

Tumor-type examples and phenotype annotations (illustrative)

Thyroid carcinoma (NTRK1/NTRK3 fusions): NTRK fusion-positive thyroid cancers include papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). (marczyk2025ntrkfusion–positivethyroid pages 1-2)

Sarcoma: NTRK fusions are present in soft tissue sarcomas (STS), with pediatric enrichment and variable histologic distribution by age. (kubota2025currentmanagementof pages 2-2, nakata2024prevalenceofneurotrophic pages 2-4)

Suggested ontology term scaffolding (for knowledge-base integration)

Because phenotypes are histology-driven, ontology annotation should generally be layered: - Primary disease layer (histology/site): e.g., “papillary thyroid carcinoma”, “soft tissue sarcoma”, “salivary gland carcinoma” (not all codes retrievable here). - Molecular feature layer: “NTRK gene fusion” (molecular abnormality).

Example HPO (symptom/sign) terms (tumor-generic, for downstream curation): - Neoplasm (HP:0002664) - Metastatic neoplasm (HP:0030800)

Example UBERON (anatomy) terms: - Thyroid gland (UBERON:0002046) (thyroid cases) (marczyk2025ntrkfusion–positivethyroid pages 1-2) - Salivary gland (UBERON:0001830) (head & neck enrichment) (nakata2024prevalenceofneurotrophic pages 2-4)

(These ontology suggestions are provided as standard mappings; specific ontology IDs were not provided in the retrieved primary sources.)

4. Genetic / Molecular Information

Causal genes

• NTRK1, NTRK2, NTRK3 (encode TRKA/TRKB/TRKC). (vingiani2023pantrkimmunohistochemistryas pages 1-3, nakata2024prevalenceofneurotrophic pages 1-2)

Fusion structure and common partners

NTRK fusions typically involve a 5’ fusion partner joined to the 3’ region of NTRK containing the kinase domain, leading to kinase activation; Vingiani et al. describe fusions as “3’ regions of NTRK genes… fused with 5’ fusion partners.” (Cancer Biomarkers; 2023-11; https://doi.org/10.3233/cbm-220357) (vingiani2023pantrkimmunohistochemistryas pages 1-3)

Examples of recurrent fusions in large cohorts include: - ETV6::NTRK3 (prominent in head & neck cancers in the Japanese cohort). (nakata2024prevalenceofneurotrophic pages 4-7, nakata2024prevalenceofneurotrophic pages 1-2) - LMNA::NTRK1 (noted among STS in Japan). (nakata2024prevalenceofneurotrophic pages 1-2) - TPM3::NTRK1 (seen as a rare IHC-negative/NGS-positive case in NSCLC in Vingiani). (vingiani2023pantrkimmunohistochemistryas pages 1-3)

Somatic vs germline

The retrieved evidence frames NTRK fusions as tumor genomic drivers detected by tumor profiling; germline NTRK fusion predisposition was not described in the retrieved sources. (nakata2024prevalenceofneurotrophic pages 2-4, bungaro2024ntrk123biologydetection pages 2-4)

Resistance variants (on-target)

Under selective pressure from TRK inhibitors, tumors can acquire on-target kinase domain mutations, including: - Solvent-front mutations: examples NTRK1 G595R and NTRK3 G623R, observed as emergent resistance in aggressive thyroid cancers treated with larotrectinib. (marczyk2025ntrkfusion–positivethyroid pages 1-2) - Resistance “via solvent-front, gatekeeper, and xDFG mutations” is described in a 2023 safety-focused review of TRK inhibitors. (yang2023safetyofcurrent pages 4-6)

5. Environmental Information

No specific environmental toxins, lifestyle factors, or infectious etiologies were identified in the retrieved sources for NTRK fusion-positive cancers as a class.

6. Mechanism / Pathophysiology

Core causal chain

1) Chromosomal rearrangement generates an NTRK fusion gene. (nakata2024prevalenceofneurotrophic pages 1-2) 2) The fusion encodes an oncogenic TRK fusion protein, functioning as an activating driver alteration. (nakata2024prevalenceofneurotrophic pages 1-2) 3) Targeted therapy with TRK inhibitors can induce tumor regression, but prolonged therapy can select for on-target resistance mutations (solvent-front, gatekeeper, xDFG). (yang2023safetyofcurrent pages 4-6, marczyk2025ntrkfusion–positivethyroid pages 1-2)

Suggested GO and CL term scaffolding (for annotation)

• GO biological processes (examples):
• Protein tyrosine kinase signaling pathway (GO:0007169)
• Positive regulation of MAPK cascade (GO:0043410) (common downstream for RTKs; included as standard mapping, not explicitly enumerated in retrieved sources)
• Cell Ontology (CL) examples (depends on tumor):
• Epithelial cell (CL:0000066) for carcinomas (thyroid, salivary)
• Mesenchymal cell (CL:0000134) for sarcomas

(These are suggested scaffolds; explicit GO/CL IDs were not provided in the retrieved sources.)

7. Anatomical Structures Affected

NTRK fusions occur across many anatomic sites; in the Japanese national clinicogenomic cohort (C-CAT), NTRK fusions were observed across 21 tumor types. (nakata2024prevalenceofneurotrophic pages 2-4)

Commonly represented sites in that cohort (adult): head and neck (including salivary), soft tissue, thyroid. (nakata2024prevalenceofneurotrophic pages 4-7, nakata2024prevalenceofneurotrophic pages 2-4)

8. Temporal Development

Onset

NTRK fusions are found in both pediatric and adult cancers, with higher prevalence in pediatric populations. (nakata2024prevalenceofneurotrophic pages 2-4, kubota2025currentmanagementof pages 1-2)

Progression

Testing is commonly performed in advanced disease. In the C-CAT cohort, most NTRK fusion-positive patients were profiled in the metastatic setting. (nakata2024prevalenceofneurotrophic pages 2-4)

9. Inheritance and Population

Epidemiology (recent statistics)

Large series consistently show that NTRK fusions are rare overall, but have strong tumor-type and age-group enrichment.

Table: This table compiles key prevalence estimates for NTRK fusion-positive cancers across large pan-cancer cohorts and sarcoma-focused analyses. It highlights the consistently low overall prevalence in adult solid tumors, contrasted with marked enrichment in pediatric and rare histologic subtypes.

Key recent datapoints: - Japan (C-CAT, 2019–2023; published 2024-06): 91/46,621 = 0.20% overall; pediatric 1.69% vs adult 0.16%; highest among large adult tumor categories were head & neck and thyroid (~1.31% each) and STS (~0.91%). (nakata2024prevalenceofneurotrophic pages 2-4, nakata2024prevalenceofneurotrophic pages 1-2) - Pan-cancer sequencing estimates summarized in 2024 review: prevalence ~0.26–0.30% in large unselected cohorts, but >90% in certain rare histologies (infantile fibrosarcoma; secretory breast carcinoma). (bungaro2024ntrk123biologydetection pages 2-4)

Population demographics

Sex ratios and detailed geographic distributions were not reported in the retrieved excerpts.

10. Diagnostics

Diagnostic strategy (current implementation)

A common real-world approach is: 1) Screen with pan-TRK immunohistochemistry (IHC), especially in tumor types where NTRK fusions are rare, to enrich candidates. 2) Confirm with nucleic-acid assays—preferably RNA-based NGS; DNA-based NGS may miss fusions due to intronic complexity.

Bungaro & Garbo note that DNA-based NGS can miss NTRK fusions “due to large intronic regions,” motivating panels “capable of detecting all NTRK rearrangements.” (Precision Cancer Medicine; 2024-09; https://doi.org/10.21037/pcm-23-19) (bungaro2024ntrk123biologydetection pages 5-6)

Test performance and pitfalls (recent data)

Vingiani et al. (2023) evaluated VENTANA pan-TRK IHC vs an RNA fusion panel in 117 evaluable cases and found: - sensitivity 91.7%, specificity 81.9%, NPV 98.8%, PPV 36.7%. (vingiani2023pantrkimmunohistochemistryas pages 1-3, vingiani2023pantrkimmunohistochemistryas media 404d7635) - among 30 IHC-positive cases, only 11 (37%) were NGS-confirmed, emphasizing the need for confirmatory testing. (vingiani2023pantrkimmunohistochemistryas pages 1-3)

Table: This table compares the main laboratory approaches used to detect NTRK fusions, summarizing their clinical role, advantages, and known pitfalls. It is useful for selecting testing strategies and understanding why screening with pan-TRK IHC is often paired with confirmatory RNA-based sequencing.

Visual evidence (diagnostic performance): tables containing the IHC vs NGS correlation and derived sensitivity/specificity/NPV/PPV were extracted from Vingiani et al. (2023). (vingiani2023pantrkimmunohistochemistryas media 404d7635)

Differential diagnosis

False-positive pan-TRK staining can occur due to physiologic/non-specific expression; in some tumor classes, IHC sensitivity/specificity are poor, particularly in sarcomas. (bungaro2024ntrk123biologydetection pages 5-6)

11. Outcome / Prognosis

Prognosis with targeted therapy (selected real-world statistic)

In a single-institution thyroid cancer cohort (n=8; published 2024-08), larotrectinib was associated with a median PFS of 24.7 months and median OS of 43.8 months. (Journal of the Endocrine Society; 2024-08; https://doi.org/10.1210/jendso/bvae158) (elghawy2024singleinstitutionexperienceof pages 1-2)

Because NTRK fusion-positive cancer spans many histologies, prognosis is highly tumor-type and stage dependent; broad, tumor-agnostic OS benchmarks were not extractable from the retrieved excerpts.

12. Treatment

Current approved/standard targeted therapies

Two first-generation TRK inhibitors are widely used as tissue-agnostic therapies: - Larotrectinib (highly selective TRK inhibitor) - Entrectinib (TRK/ROS1/ALK inhibitor with CNS penetration)

A 2023 safety review summarized pooled larotrectinib outcomes and reported: ORR 69% (95% CI 63–75) and median DOR 32.9 months (95% CI 27.3–41.7). (Expert Opinion on Drug Safety; 2023-10; https://doi.org/10.1080/14740338.2023.2274426) (yang2023safetyofcurrent pages 4-6)

Entrectinib integrated adult outcomes summarized in the same review include ORR 61% and median DOR 13.8 months (with intracranial ORR 63.6% noted). (yang2023safetyofcurrent pages 4-6)

Next-generation TRK inhibitors (post-resistance)

• Repotrectinib (TRIDENT-1 phase 1/2): In NTRK fusion-positive solid tumors, ORR was 59% (44–72) in TRK TKI–naive patients (n=51) and 48% (36–60) in TRK TKI–pretreated patients (n=69). Median PFS was 30.3 months (TKI-naive) and 7.4 months (TKI-pretreated). Among pretreated patients with solvent-front mutations, ORR was 53% (34–72). (Nature Medicine; 2026-02; https://doi.org/10.1038/s41591-025-04079-7) (besse2026repotrectinibinntrk pages 1-2)
• Selitrectinib: In thyroid carcinoma with acquired solvent-front mutations after larotrectinib, 3 patients treated with selitrectinib had partial responses (but durability in ATC was limited). (marczyk2025ntrkfusion–positivethyroid pages 1-2)

Table: This table summarizes currently available efficacy, safety, and regulatory information for first- and next-generation TRK inhibitors used in NTRK fusion-positive cancers. It is useful for comparing approved therapies with emerging resistance-directed agents across pooled trials and thyroid-specific real-world data.

Resistance mechanisms (clinically important)

Acquired on-target mutations—especially solvent-front mutations—are recurrent resistance mechanisms: - NTRK3 G623R and NTRK1 G595R were observed after larotrectinib in PDTC/ATC and were associated with progression. (marczyk2025ntrkfusion–positivethyroid pages 1-2)

Adverse events / real-world safety signals

• Repotrectinib: dizziness was the most common treatment-related adverse event (57%), and discontinuation due to TRAE occurred in 4%. (besse2026repotrectinibinntrk pages 1-2)
• Larotrectinib pooled safety summary reported low rates of grade ≥3 events and commonly noted hematologic and hepatic laboratory abnormalities. (bungaro2024ntrk123biologydetection pages 5-6, yang2023safetyofcurrent pages 4-6)

MAXO (treatment action) suggestions

• TRK inhibitor therapy (targeted therapy; tumor-agnostic)
• Molecular tumor profiling / NGS-guided therapy selection

(MAXO term IDs were not available in the retrieved sources.)

13. Prevention

Primary prevention

No established primary prevention exists for NTRK fusion formation in cancers as a class (not addressed in retrieved sources).

Secondary prevention (early detection / screening)

The principal prevention-like strategy is secondary prevention through systematic molecular testing, enabling earlier deployment of effective targeted therapy. International practice patterns support screening (often IHC) and confirmatory sequencing workflows, particularly in low-prevalence tumors. (vingiani2023pantrkimmunohistochemistryas pages 1-3, bungaro2024ntrk123biologydetection pages 5-6)

14. Other Species / Natural Disease

No veterinary or cross-species naturally occurring NTRK fusion-positive cancer evidence was identified in the retrieved sources.

15. Model Organisms

No specific animal model organisms or engineered in vivo models were described in the retrieved excerpts. This is a gap in the currently retrieved evidence set; additional targeted searches in model-organism databases (MGI/IMPC) and translational NTRK fusion modeling literature would be required.

Recent Developments and Real-World Implementations (2023–2024 emphasis)

1) National-scale prevalence estimates with pediatric enrichment: Nakata et al. (2024-06) quantified low overall prevalence (0.20%) but substantially higher pediatric prevalence (1.69%) in a national clinicogenomic cohort. (nakata2024prevalenceofneurotrophic pages 2-4, nakata2024prevalenceofneurotrophic pages 1-2) 2) Operational diagnostic workflows and performance metrics: Vingiani et al. (2023-11) provided real-world screening performance for pan-TRK IHC with high NPV but low PPV, reinforcing reflex NGS confirmation. (vingiani2023pantrkimmunohistochemistryas pages 1-3, vingiani2023pantrkimmunohistochemistryas media 404d7635) 3) Growing emphasis on resistance-aware sequencing and next-generation inhibitors: 2023–2024 expert reviews emphasize acquired resistance mechanisms (solvent-front/gatekeeper/xDFG) and newer agents designed to overcome them. (yang2023safetyofcurrent pages 4-6, bungaro2024ntrk123biologydetection pages 5-6)

Notes on PMID requirement

Several of the retrieved sources are indexed by DOI and journal metadata, but PMIDs were not available in the retrieved excerpts for most of the key 2023–2024 papers. Where PMIDs are required for knowledge-base ingestion, an additional PubMed-specific retrieval step would be needed.

References

1. (bungaro2024ntrk123biologydetection pages 5-6): Maristella Bungaro and Edoardo Garbo. Ntrk1/2/3: biology, detection and therapy. Precision Cancer Medicine, 6:3-3, Sep 2024. URL: https://doi.org/10.21037/pcm-23-19, doi:10.21037/pcm-23-19. This article has 11 citations.

2. (vingiani2023pantrkimmunohistochemistryas pages 1-3): Andrea Vingiani, Daniele Lorenzini, Elena Conca, Chiara Costanza Volpi, Desirè Viola Trupia, Annunziata Gloghini, Federica Perrone, Elena Tamborini, Gian Paolo Dagrada, Luca Agnelli, Iolanda Capone, Adele Busico, and Giancarlo Pruneri. Pan-trk immunohistochemistry as screening tool for ntrk fusions: a diagnostic workflow for the identification of positive patients in clinical practice. Cancer Biomarkers, 38:301-309, Nov 2023. URL: https://doi.org/10.3233/cbm-220357, doi:10.3233/cbm-220357. This article has 10 citations and is from a peer-reviewed journal.

3. (yang2023safetyofcurrent pages 4-6): Adeline T. Yang and Theodore Willis Laetsch. Safety of current treatment options for ntrk fusion-positive cancers. Expert Opinion on Drug Safety, 22:1073-1089, Oct 2023. URL: https://doi.org/10.1080/14740338.2023.2274426, doi:10.1080/14740338.2023.2274426. This article has 9 citations and is from a peer-reviewed journal.

4. (nakata2024prevalenceofneurotrophic pages 2-4): Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, and Shinji Kohsaka. Prevalence of neurotrophic tropomyosin receptor kinase (ntrk) fusion gene positivity in patients with solid tumors in japan. Cancer Medicine, Jun 2024. URL: https://doi.org/10.1002/cam4.7351, doi:10.1002/cam4.7351. This article has 13 citations and is from a peer-reviewed journal.

5. (besse2026repotrectinibinntrk pages 1-2): Benjamin Besse, Jessica J. Lin, Lyudmila Bazhenova, Koichi Goto, Adrianus Johannes de Langen, Dong-Wan Kim, Jürgen Wolf, Christoph Springfeld, Sanjay Popat, Darren W. T. Lim, Misako Nagasaka, Jung Yong Hong, Christina S. Baik, Alice Hervieu, Victor Moreno, Nong Yang, Kanthi Kollengode, Haisu Yang, Yuanfang Xu, Christophe Y. Calvet, Yong Yuan, Amy B. Hammell, Alexander Drilon, and Benjamin J. Solomon. Repotrectinib in ntrk fusion–positive advanced solid tumors: a phase 1/2 trial. Nature Medicine, 32:682-689, Feb 2026. URL: https://doi.org/10.1038/s41591-025-04079-7, doi:10.1038/s41591-025-04079-7. This article has 1 citations and is from a highest quality peer-reviewed journal.

6. (bungaro2024ntrk123biologydetection pages 2-4): Maristella Bungaro and Edoardo Garbo. Ntrk1/2/3: biology, detection and therapy. Precision Cancer Medicine, 6:3-3, Sep 2024. URL: https://doi.org/10.21037/pcm-23-19, doi:10.21037/pcm-23-19. This article has 11 citations.

7. (nakata2024prevalenceofneurotrophic pages 1-2): Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, and Shinji Kohsaka. Prevalence of neurotrophic tropomyosin receptor kinase (ntrk) fusion gene positivity in patients with solid tumors in japan. Cancer Medicine, Jun 2024. URL: https://doi.org/10.1002/cam4.7351, doi:10.1002/cam4.7351. This article has 13 citations and is from a peer-reviewed journal.

8. (kubota2025currentmanagementof pages 1-2): Yuta Kubota, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, Nobuhiro Kaku, Toshifumi Ozaki, and Kazuhiro Tanaka. Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. Japanese Journal of Clinical Oncology, 55:313-326, Feb 2025. URL: https://doi.org/10.1093/jjco/hyaf015, doi:10.1093/jjco/hyaf015. This article has 6 citations and is from a peer-reviewed journal.

9. (marczyk2025ntrkfusion–positivethyroid pages 1-2): Vicente R. Marczyk, Sasan Fazeli, Ramona Dadu, Naifa L. Busaidy, Priyanka Iyer, Mimi I. Hu, Steven I. Sherman, Sarah Hamidi, Sayed Mohsen Hosseini, Michelle D. Williams, Salmaan Ahmed, Mark J. Routbort, Raja Luthra, Sinchita Roy-Chowdhuri, Francis Anthony San Lucas, Keyur P. Patel, David S. Hong, Mark Zafereo, Jennifer R. Wang, Anastasios Maniakas, Steven G. Waguespack, and Maria E. Cabanillas. Ntrk fusion–positive thyroid carcinoma: from diagnosis to targeted therapy. JCO Precision Oncology, Jan 2025. URL: https://doi.org/10.1200/po.24.00321, doi:10.1200/po.24.00321. This article has 10 citations and is from a peer-reviewed journal.

10. (kubota2025currentmanagementof pages 2-2): Yuta Kubota, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, Nobuhiro Kaku, Toshifumi Ozaki, and Kazuhiro Tanaka. Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. Japanese Journal of Clinical Oncology, 55:313-326, Feb 2025. URL: https://doi.org/10.1093/jjco/hyaf015, doi:10.1093/jjco/hyaf015. This article has 6 citations and is from a peer-reviewed journal.

11. (nakata2024prevalenceofneurotrophic pages 4-7): Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, and Shinji Kohsaka. Prevalence of neurotrophic tropomyosin receptor kinase (ntrk) fusion gene positivity in patients with solid tumors in japan. Cancer Medicine, Jun 2024. URL: https://doi.org/10.1002/cam4.7351, doi:10.1002/cam4.7351. This article has 13 citations and is from a peer-reviewed journal.

12. (nakata2024prevalenceofneurotrophic pages 7-9): Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, and Shinji Kohsaka. Prevalence of neurotrophic tropomyosin receptor kinase (ntrk) fusion gene positivity in patients with solid tumors in japan. Cancer Medicine, Jun 2024. URL: https://doi.org/10.1002/cam4.7351, doi:10.1002/cam4.7351. This article has 13 citations and is from a peer-reviewed journal.

13. (vingiani2023pantrkimmunohistochemistryas media 404d7635): Andrea Vingiani, Daniele Lorenzini, Elena Conca, Chiara Costanza Volpi, Desirè Viola Trupia, Annunziata Gloghini, Federica Perrone, Elena Tamborini, Gian Paolo Dagrada, Luca Agnelli, Iolanda Capone, Adele Busico, and Giancarlo Pruneri. Pan-trk immunohistochemistry as screening tool for ntrk fusions: a diagnostic workflow for the identification of positive patients in clinical practice. Cancer Biomarkers, 38:301-309, Nov 2023. URL: https://doi.org/10.3233/cbm-220357, doi:10.3233/cbm-220357. This article has 10 citations and is from a peer-reviewed journal.

14. (demols2023atwostepdiagnostic pages 6-6): Anne Demols, Laureen Rocq, Luis Perez-Casanova, Manon Charry, Nancy De Nève, Ali Ramadhan, Claude Van Campenhout, Sarah De Clercq, Calliope Maris, Jean Closset, Valerio Lucidi, Isabelle Salmon, and Nicky D’Haene. A two-step diagnostic approach for ntrk gene fusion detection in biliary tract and pancreatic adenocarcinomas. The Oncologist, 28:e520-e525, Mar 2023. URL: https://doi.org/10.1093/oncolo/oyad075, doi:10.1093/oncolo/oyad075. This article has 16 citations.

15. (elghawy2024singleinstitutionexperienceof pages 1-2): Omar Elghawy, Adam Barsouk, A. Heidlauf, Simon Chen, Roger B. Cohen, and Lova L. Sun. Single-institution experience of larotrectinib therapy for patients with ntrk fusion-positive thyroid carcinoma. Journal of the Endocrine Society, Aug 2024. URL: https://doi.org/10.1210/jendso/bvae158, doi:10.1210/jendso/bvae158. This article has 6 citations and is from a peer-reviewed journal.

16. (theik2024ntrktherapyamong pages 4-6): Nyein Wint Yee Theik, Meri Muminovic, Andres M. Alvarez-Pinzon, Ahmed Shoreibah, Atif M. Hussein, and Luis E. Raez. Ntrk therapy among different types of cancers, review and future perspectives. International Journal of Molecular Sciences, 25:2366, Feb 2024. URL: https://doi.org/10.3390/ijms25042366, doi:10.3390/ijms25042366. This article has 28 citations.

17. (besse2026repotrectinibinntrk pages 5-7): Benjamin Besse, Jessica J. Lin, Lyudmila Bazhenova, Koichi Goto, Adrianus Johannes de Langen, Dong-Wan Kim, Jürgen Wolf, Christoph Springfeld, Sanjay Popat, Darren W. T. Lim, Misako Nagasaka, Jung Yong Hong, Christina S. Baik, Alice Hervieu, Victor Moreno, Nong Yang, Kanthi Kollengode, Haisu Yang, Yuanfang Xu, Christophe Y. Calvet, Yong Yuan, Amy B. Hammell, Alexander Drilon, and Benjamin J. Solomon. Repotrectinib in ntrk fusion–positive advanced solid tumors: a phase 1/2 trial. Nature Medicine, 32:682-689, Feb 2026. URL: https://doi.org/10.1038/s41591-025-04079-7, doi:10.1038/s41591-025-04079-7. This article has 1 citations and is from a highest quality peer-reviewed journal.

18. (bungaro2024ntrk123biologydetection pages 8-9): Maristella Bungaro and Edoardo Garbo. Ntrk1/2/3: biology, detection and therapy. Precision Cancer Medicine, 6:3-3, Sep 2024. URL: https://doi.org/10.21037/pcm-23-19, doi:10.21037/pcm-23-19. This article has 11 citations.